Publications by authors named "Suguru Matsuda"
Objectives: The current standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC) is concurrent chemoradiation therapy (CCRT) followed by durvalumab consolidation therapy. Although the trial revealed the survival benefit of adding an immune checkpoint inhibitor (ICI) to the population, the optimal treatment strategy and efficacy of subsequent treatment after relapse remain unclear.
Materials And Methods: We retrospectively collected data from patients with unresectable LA-NSCLC who completed platinum-based CCRT as first-line treatment.
Article Synopsis
- Chemotherapy-induced anorexia occurs in 13.2% of patients with advanced lung cancer, leading to significant weight loss within the first 9 weeks of treatment.
- The study, reviewing 106 patients undergoing platinum-based chemotherapy and immune checkpoint inhibitors, found that those with anorexia had shorter progression-free and overall survival, although the results were not statistically significant.
- The findings emphasize the need for enhanced supportive care to manage chemotherapy-induced anorexia and minimize its impact on weight loss and treatment outcomes.
Background: Anamorelin is a selective ghrelin receptor agonist approved for cancer cachexia in Japan. Little is known about predictors of anamorelin efficacy. This study aimed to assess the effect of diabetes on the efficacy and safety of anamorelin in patients with cancer cachexia.
View Article and Find Full Text PDFBackground: The association between the development of checkpoint inhibitor pneumonitis (CIP) with tumor response and survival has remained unclear so far. The aim of the present study was to evaluate the association between CIP and the clinical efficacy of anti-programmed cell death-1 antibody in patients with advanced non-small cell lung cancer (NSCLC).
Methods: Between January 2016 and August 2019, 203 advanced NSCLC patients were administered with nivolumab or pembrolizumab.